We assessed the accuracy of the UISS (UCLA Integrated Staging System) to predict the postoperative recurrence of renal cell carcinoma. We also evaluated whether including patient age and tumor histology would improve clinical decision making. Materials and Methods: We analyzed the records of 1,630 patients treated with nephrectomy at a single academic center. The accuracy of the UISS model to predict early (12 months or less) and late (more than 60 months) recurrence after surgery was compared with a new model including patient age and disease histology.
DESPITE the efficacy of current treatments 20% to 30% of patients with localized RCC experience disease recurrence during followup.
1e3 Previous reports support the benefit of early treatment of metastases and local recurrences after surgery. 4e7 Similarly although the advantage of systemic therapy in the postoperative setting remains controversial, 8, 9 the timely detection of metastases could affect survival. 10 There is as yet no consensus regarding the optimal followup protocol after surgery for RCC. 11 The design of an effective surveillance protocol requires accurate stratification of the risk of postoperative recurrence. The Accepted for publication January 16, 2018 . No direct or indirect commercial incentive associated with publishing this article.
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Supported by National Cancer Institute Cancer Center Support Grant P30-CA008748 (Memorial Sloan Kettering Cancer Center). Commonly available prognostic factors such as patient age and tumor histology are not considered by the UISS risk model. Kidney cancer histology subtypes have been associated with the risk of recurrence 17e19 and previous studies showed better oncologic outcomes in young patients. 20 The 2 factors can be easily assessed by the physician when counseling the patient for postoperative followup.
For these reasons we were interested in testing the accuracy of the UISS risk stratification system to predict RCC recurrence after treatment and assess the clinical benefit of adding patient age and tumor histology to the UISS model. We evaluated 2 clinical scenarios, including 1) early recurrencedwithin 1 year after surgery and 2) late recurrenced5 years postoperatively and beyond.
Accurate prediction of early recurrence can help determine the need for and the frequency of imaging studies in postoperative year 1. If a patient is at low risk for recurrence by 12 months, imaging before 12 months could be avoided. Predicting late recurrence is helpful to plan the discontinuation of imaging. The EAU Guidelines suggest stopping surveillance in men at low risk when they remain recurrence-free for 5 years postoperatively. 16 The AUA guidelines 12 and the NCCN Guidelines 13 leave the decision up to the judgment of the physician after 5 years or before for patients at low risk.
PATIENTS AND METHODS
Data were collected on a cohort of 2,359 patients with RCC treated with radical or partial nephrectomy from January 1995 to June 2016 at a single academic center. All patients had histology proven malignant disease and were free of metastases at preoperative staging. Clinical and pathological data, including the ECOG PS score, pathological stage (TNM classification), Fuhrman grade and histology were collected for each patient. No patient received neoadjuvant or adjuvant therapy.
The followup protocol was based on clinical evaluation and chest-abdomen computerized tomography performed 3 to 6 and 12 months after surgery in year 1 and annually thereafter. Bone scan and brain imaging were done only when clinically indicated. Additional interim evaluations were performed throughout followup if patient symptoms raised clinical suspicion of relapse.
Relapse after treatment was defined as local recurrence or distant metastases demonstrable on imaging at least 1 month after treatment. Patients who did not experience relapse were censored at the date of the last followup. The 128 patients (6%) missing clinical or pathological data were excluded from analysis. Moreover, 601 patients (25%) were lost to followup since a relevant proportion residing in regions far from our center were frequently followed elsewhere after surgery regardless of disease characteristics.
The aim of the study was to compare the UISS model, which includes TNM pathological staging, ECOG PS score and Fuhrman grade, and further stratifies patients into low, intermediate and high risk categories, 15 to a new model that includes age and tumor histology to follow patients after surgery for RCC. The 2 models were compared based on accuracy for predicting early postoperative recurrence (within posttreatment year 1).
According to our protocol patients scheduled for a 12-month posttreatment scan could have been assessed as much as 3 months later. Therefore, all patients in whom recurrence was detected 15 months or less after surgery were considered for study inclusion. A complete longitudinal followup assessment was not available in all patients. Thus, to properly assess the risk of early relapse we considered for outcome assessment only patients with at least 1 negative followup assessment within 10 to 15 months after surgery or those with subsequent negative followup evaluations. We excluded from study the 81 patients (4.9%) with a last negative evaluation before 10 months postoperatively and the 120 (7.3%) with relapse after 15 months postoperatively but without a previous negative evaluation within 10 to 15 months. The early recurrence subcohort comprised 1,429 patients (88%).
Logistic regression analysis was done with early recurrence considered a binary outcome. Using the AUC we evaluated the accuracy of the UISS model, considering the model with separate variables and the simplified risk group categorization, and the new model. The estimated probability of early recurrence according to the 2 models was stratified by disease histology and displayed graphically.
We performed decision curve analysis to evaluate the clinical consequences of model predictions by comparing the net benefit, based on positive and false-positive findings, at various threshold probabilities of recurrence. 21 Because it is unlikely that a physician would order imaging if the probability of relapse was less than 5%, or would avoid imaging if the probability of relapse was greater than 20%, we examined the range of probabilities at a threshold between 5% and 20%. The accuracy of the models and the decision curves was corrected for overfitting using tenfold cross validation.
As a second study aim we tested whether the risk stratification system was accurate for predicting late RCC recurrence. We performed a landmark time analysis in the subset of patients who were recurrence-free 5 years after surgery. Only those with a followup evaluation after 60 months postoperatively were considered to assess this outcome. The late recurrence subcohort comprised 669 patients (41%). We performed Cox regression analysis to test the accuracy of the 2 models in this patient subset. The cumulative incidence of late recurrence according to UISS risk categories was calculated and graphically displayed using Kaplan-Meier analysis. Statistical analyses were performed with StataÒ, version 13.0. Table 1 lists clinical and pathological characteristics of the entire cohort. The most frequent histology at postoperative pathological evaluation was clear cell in 1,273 cases (78%). Papillary types 1 and 2, and chromophobe tumors were found in 137 (8.4%), 113 (6.9%) and 107 cases (6.6%), respectively.
RESULTS

Early Recurrence
Overall 221 patients (15.4%) experienced recurrence within year 1 after surgery. The 2 tested models were highly predictive of early recurrence ( Decision curve analysis demonstrated that the UISS model and the new model were associated with a good net benefit to discriminate patients at higher risk for recurrence who needed to be followed within year 1 after treatment rather than waiting to assess them at 12 months ( fig. 1) . The 2 models performed better compared in protocols in which all or no patients were scanned within posttreatment year 1 when examined within the threshold recurrence probability of 5% to 20%. The net benefit was lower when patients were grouped in a risk categorization system. Figure 2 shows the adjusted estimated probability of early recurrence according to the 2 models stratified for histological subtypes. The average probability of recurrence in patients with low risk histology (eg papillary type 1 and chromophobe tumors) differed significantly according to the 2 models. For the UISS model vs the model including histology the average probability of recurrence was 1.6% vs 0.6% in the low risk category, 5.5% vs 1.9% in the intermediate risk category and 45% vs 22% in the high risk category. Table 3 shows the Cox regression analysis predicting late recurrence in patients who were free of disease 60 months postoperatively. Of these patients 60% were followed at least 8 years. No variable was significantly associated with late recurrence. The Kaplan-Meier analysis predicted a probability of relapse at 96 months of 5% (95% CI 2e10), 6% (95% CI 4e9) and 13% (95% CI 6e10) in patients in the low, intermediate and high risk categories, respectively ( fig. 3 ). There was no significant difference among the groups (p ¼ 0.2).
Late Recurrence
DISCUSSION
We assessed the accuracy of the UISS model to predict the risk of early recurrence after surgery for RCC compared with a new model including 2 additional and easily available variables, namely patient age and tumor histology. Our results showed a lower risk of early recurrence postoperatively in patients with chromophobe disease compared with those who had clear cell or papillary type 2 disease. Patient age did not affect the risk of recurrence. The accuracy of the UISS model to predict early recurrence was not significantly improved by including age and disease histology. Moreover, we found no difference in clinical benefit when the UISS model or the new model was used to select patients for imaging to detect early postoperative recurrence within posttreatment year 1. Tumor histology may be of particular value in patients in the intermediate risk category, who could be spared additional radiological examinations. Patients in the UISS intermediate risk category showed a 1.9% probability of early recurrence in the presence of chromophobe or papillary type 1 disease. This is comparable to the 1.6% probability of recurrence estimated in patients in the low risk category regardless of pathological findings. When patients with low risk features were diagnosed with low risk histology, the probability of recurrence decreased to an average of 0.6%, eventually questioning the need to follow these patients within year 1 after surgery.
The UISS model has been shown to accurately predict recurrence-free survival, outperforming other prognostic models. 15, 22 Lam et al reported 90.4%, 61.8% and 41.9% 5-year recurrence-free survival in patients in the low, intermediate and high risk UISS categories, respectively.
23 Likewise the effect of including patient age and disease histology in prognostic models for RCC has been previously investigated. In a large multicenter data set of 13,107 patients advanced age was independently associated with a higher risk of early recurrence.
24
However, the investigators defined early recurrence as within 5 years postoperatively rather than within 1 year as in our study. Other series showed better disease specific survival in young men with RCC, 20, 25, 26 although younger patients may have received more aggressive treatments when recurrence developed. In line with our findings others reported no significant effect of patient age on the risk of recurrence after surgery for RCC when these data were included in multivariable models.
26,27
Histological subtypes have been shown to independently affect the outcome of RCC cases.
17e19,28
Better prognosis has been demonstrated for chromophobe and papillary type 1 tumors compared with the clear cell and papillary type 2 subtypes. 16, 18, 19, 29 After accounting for other predictive factors Leibovich et al reported a higher risk of metastases in patients with clear cell disease compared with papillary and chromophobe subtypes in a series of 3,062 patients surgically treated for RCC. 28 In line with our results including disease histology in prognostic models did not have a large impact on the predictive accuracy of oncologic outcomes after RCC treatment. 18, 19 However, we provide evidence to show that including histological subtypes when assessing the risk of recurrence could lead to significant re-estimation of patient risk according to a strong predictive model such as the UISS.
As a second study aim we tested the accuracy of the UISS model to predict recurrence after 60 months postoperatively. The EAU guidelines recommend discontinuing surveillance after 5 years in patients in the low risk UISS category while a biannual assessment is suggested in those in the intermediate or high risk category. 16 Conversely the AUA guidelines 12 and the NCCN Guidelines 13 do not provide clear recommendations, leaving the decision on when to stop surveillance to physician judgment.
In our series patients at low risk for recurrence according to the UISS model showed a 5% probability of relapse 8 years after surgery with no significant difference compared with the intermediate risk group. Graphically patients in the high risk group seemed to have a higher probability of recurrence, although this did not significantly differ compared to the other groups. These findings suggest that stopping the surveillance protocol based on a risk stratification system could be ineffective.
It was previously reported that discharging patients from surveillance after 5 years or even earlier according to risk profiles could result in up to a 33% rate of nondetected recurrences. 14 These results support previous findings suggesting that an individualized approach to followup based on the interplay of competing factors such as patient comorbidities should be adopted to counsel patients about the duration of followup rather than relying on disease characteristics alone.
30
Our study is not devoid of limitations. Given its retrospective design, bias in patient selection could not be ruled out. Although our followup protocol was standardized in all patients, some with higher risk features may have received more stringent followup than others at least in the early posttreatment period. For this reason, rather than performing a time to event analysis assessing predictors throughout the entire followup, we assessed the probability of early and late recurrences as the most clinically relevant outcomes with direct impact on the design of the followup protocol.
Moreover, 25% of the patients were lost to followup and excluded from analysis. However, on sensitivity analysis the patients with missing followup data did not significantly differ from the study cohort in terms of preoperative disease characteristics (all p >0.05). A relatively small number of patients were at risk for recurrence 60 months after treatment, which could explain the nonsignificant difference in the probability of late recurrence among the risk group categories. Clearly there is a need for larger prospective trials to investigate the predictors of late recurrence of RCC postoperatively.
CONCLUSIONS
Our results support the use of a prognostic model such as the UISS to stratify the risk of early recurrence of RCC after surgery to tailor the followup protocol in the early period. However, less stringent followup could be recommended for patients with low risk histology regardless of the risk category. We did not find evidence for stopping the surveillance protocol according to UISS risk categories, although larger prospective studies are needed to clarify the appropriate duration of postoperative surveillance. 
